Parenteral Manual

Prochlorperazine mesylate

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Antiemetic; Antipsychotic
Original Date: 
August 2005
Revised Date: 
December 2019

Treatment of:

  • Nausea and vomiting
  • Psychiatric disorders
Reconstitution and Stability: 
  • Stable at room temperature                                                                
  • Protect from light - slightly yellow colour does not affect potency; markedly discoloured solutions should be discarded                                                                    

- Solutions Compatible: dextrose solutions up to D10W, NS, dextrose-saline combinations, ringer's solution, ringer's lactate

- Additive/buretrol Compatible: codeine, meperidine, morphine

- Y-site Compatible: KCl (up to 40 mmol/L), TPN (amino acids/dextrose)

- Incompatible: Many medications- do not mix with other medications


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IM YES, preferred
IV Direct


IV Intermittent Infusion YES, Not Recommended, BP monitoring
Usual dilution: 1 mg/mL
Infusion time: over 30 minutes
IV Continuous Infusion NO





(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric: (For children >9 kg or >2 years): IV NOT RECOMMENDED
- Antiemetic:

  • 0.1-0.15 mg/kg/dose IM/IV Q 8-12 hours
  • Maximum: 40 mg daily

- Treatment of psychoses:

  • 0.13 mg/kg/dose IM, change to oral as soon as possible

- Antiemetic:

  • 2.5-10 mg IV; may repeat Q 3-4 hours as required
  • 5-10 mg IM Q 3-4 hours
  • Maximum: 40 mg daily

- Treatment of psychoses:

  • 10-20 mg IM Q 4 hours PRN; change to oral as soon as possible
Potential hazards of parenteral administration: 
  • Sedation, tachycardia, hypotension, dermatitis
  • CNS depression, respiratory and/or vasomotor collapse
  • Extrapyramidal symptoms (tremor, rigidity, occulogyric crisis) are common in children; Treatment = diphenhydramine 1 mg/kg IV stat          
  • Arrhythmias, neuroleptic malignant syndrome (rigidity, hyperthermia, decreased consciousness)
  • Hypersensitivity reactions

Keep patients supine for at least ½ hour after administration (hypotension with IV use) Monitor blood pressure during IV use Caution in severe cardiac or liver disease, epilepsy, severe hypertension or hypotension May potentiate the action of CNS depressants

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.